<DOC>
	<DOCNO>NCT00265798</DOCNO>
	<brief_summary>This phase II trial study well sorafenib work treat patient malignant gastrointestinal stromal tumor progress previous treatment imatinib mesylate sunitinib malate . Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor .</brief_summary>
	<brief_title>Sorafenib Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During After Previous Treatment With Imatinib Mesylate Sunitinib Malate</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine objective response rate patient imatinib sunitinib-resistant malignant gastrointestinal stromal tumor treat BAY 43-9006 . SECONDARY OBJECTIVES : I . To determine toxicity experienced patient imatinib sunitinib -resistant malignant gastrointestinal stromal tumor treat BAY 43-9006 . II . To determine progression-free survival overall survival patient imatinib sunitinib -resistant malignant gastrointestinal stromal tumor treat BAY 43-9006 . TERTIARY OBJECTIVES : I . To examine mutational status KIT PDGFA patient imatinib- sunitinib resistant malignant gastrointestinal stromal tumor correlate response BAY 43-9006 . OUTLINE : This multicenter study . Patients stratify accord response prior treatment imatinib mesylate sunitinib malate ( imatinib mesylate- sunitinib malate-responsive disease v primary imatinib mesylate- sunitinib malate-refractory disease ) . Patients receive oral sorafenib twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm gastrointestinal stromal tumor Not amenable curative surgery Kitexpressing tumor Disease progression ( i.e. , new lesion 20 % increase unidimensional tumor size ) treatment imatinib mesylate sunitinib malate Measurable disease , define ≥ 1 unidimensionally measurable lesion &gt; 20 mm conventional technique OR &gt; 10 mm spiral CT scan Only site measurable disease must outside previously irradiated area No known brain metastasis Performance status ECOG 02 More 3 month Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Bilirubin normal AST ALT &lt; 2.5 time upper limit normal Creatinine ≤ 1.5 mg/dL Creatinine clearance &gt; 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No uncontrolled hypertension Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No history allergic reaction attribute compound similar chemical biological composition sorafenib No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness No evidence bowel perforation obstruction No prior angiogenesis inhibitor No immunotherapy last dose imatinib mesylate sunitinib malate No chemotherapy chemoembolization therapy last dose imatinib mesylate sunitinib malate See Disease Characteristics At least 4 week since prior radiotherapy recover At least 14 day since prior imatinib mesylate sunitinib malate No prior sorafenib No prior inhibitor MAPKsignaling intermediate No investigational agent last dose imatinib mesylate sunitinib malate Concurrent anticoagulation therapy warfarin allow provide follow criterion meet : On therapeutic stable warfarin dose INR ≤3 No active bleed pathologic condition confers high risk bleed No concurrent combination antiretroviral therapy HIVpositive patient No concurrent administration follow : Enzymeinducing antiepileptic drug ( e.g. , carbamazepine , phenytoin , phenobarbital ) Hypericum perforatum ( St. John 's wort ) Rifampin No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>